PNTG Stock Analysis: Pennant | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 1.407m USD | 12M Return: 56.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.1M
EPS Trend: 98.4%
Qual. Beats: 0
Rev. Trend: 99.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 6.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Pennant Group, Inc. (PNTG) is a U.S.-based provider of home health, hospice, and senior living services, operating across two reportable segments: Home Health and Hospice Services, and Senior Living Services. The company offers a range of clinical services including nursing, therapy (speech, occupational, and physical), medical social work, and home health aide support, as well as hospice care focused on the physical, spiritual, and psychosocial needs of terminally ill patients and their families. Its senior living segment provides residential accommodations, meals, housekeeping, and assistance with daily living for both independent seniors and those requiring some level of support.
Pennant operates home health, hospice, and home care agencies, along with senior living communities, in 15 U.S. states spanning the West, South, and Midwest, including Alabama, Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Tennessee, Texas, Utah, Washington, Wisconsin, and Wyoming. The company was incorporated in 2019 and is headquartered in Eagle, Idaho, and it was spun off from The Ensign Group in late 2019 as an independent public company.
As a participant in the post-acute and senior care sector, Pennant operates within the GICS Health Care Facilities sub-industry, an area whose underlying demand is shaped by demographic trends such as the aging U.S. population and a growing preference for in-home and community-based care over institutional settings.
- Home health and hospice segment revenue accelerates on aging demographics
- Medicare rate adjustments pressure home health operating margins
- Senior living occupancy recovery supports segment revenue growth
| Net Income: 30.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.78 > 1.0 |
| NWC/Revenue: 2.37% < 20% (prev 4.80%; Δ -2.43% < -1%) |
| CFO/TA 0.07 > 3% & CFO 66.1m > Net Income 30.3m |
| Net Debt (731.0m) to EBITDA (60.0m): 12.18 < 3 |
| Current Ratio: 1.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (35.8m) vs 12m ago 1.58% < -2% |
| Gross Margin: 14.78% > 18% (prev 13.71%; Δ 1.07% > 0.5%) |
| Asset Turnover: 120.4% > 50% (prev 100.6%; Δ 19.76% > 0%) |
| Interest Coverage Ratio: 5.94 > 6 (EBIT TTM 50.7m / Interest Expense TTM 8.54m) |
| A: 0.03 (Total Current Assets 152.8m - Total Current Liabilities 128.6m) / Total Assets 956.5m |
| B: 0.10 (Retained Earnings 95.3m / Total Assets 956.5m) |
| C: 0.06 (EBIT TTM 50.7m / Avg Total Assets 850.1m) |
| D: 0.61 (Book Value of Equity 346.0m / Total Liabilities 567.0m) |
| Altman-Z'' = 1.53 = BB |
| DSRI: 0.95 (Receivables 122.8m/95.0m, Revenue 1.02b/748.2m) |
| GMI: 0.93 (GM 13.71% / 14.78%) |
| AQI: 1.22 (AQ_t 0.49 / AQ_t-1 0.40) |
| SGI: 1.37 (Revenue 1.02b / 748.2m) |
| TATA: -0.04 (NI 30.3m - CFO 66.1m) / TA 956.5m) |
| Beneish M = -2.75 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 40.50 with a total of 266,329 shares traded. Over the past week, the price has changed by +5.14%, over one month by +25.39%, over three months by +32.01% and over the past year by +56.92%.
Current recommended Stop Loss: 38.30 (which is 5.4% or 1.4 ATR below the current price).
Pennant has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold PNTG.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 40.8 | 0.8% |
P/E Trailing = 45.4607
P/E Forward = 29.3255
P/S = 1.3748
P/B = 3.9376
P/EG = 2.258
Revenue TTM = 1.02b USD
EBIT TTM = 50.7m USD
EBITDA TTM = 60.0m USD
Long Term Debt = 164.7m USD (from longTermDebt, last quarter)
Short Term Debt = 36.9m USD (from shortTermDebt, last quarter)
Debt = 735.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 283.1m
Net Debt = 731.0m USD (calculated: Debt 735.9m - CCE 4.91m)
Enterprise Value = 2.14b USD (1.41b + Debt 735.9m - CCE 4.91m)
Interest Coverage Ratio = 5.94 (Ebit TTM 50.7m / Interest Expense TTM 8.54m)
EV/FCF = 45.15x (Enterprise Value 2.14b / FCF TTM 47.3m)
FCF Yield = 2.21% (FCF TTM 47.3m / Enterprise Value 2.14b)
FCF Margin = 4.63% (FCF TTM 47.3m / Revenue TTM 1.02b)
Net Margin = 2.96% (Net Income TTM 30.3m / Revenue TTM 1.02b)
Gross Margin = 14.78% ((Revenue TTM 1.02b - Cost of Revenue TTM 872.0m) / Revenue TTM)
Gross Margin QoQ = 13.10% (prev 12.93%)
Tobins Q-Ratio = 2.23 (Enterprise Value 2.14b / Total Assets 956.5m)
Interest Expense / Debt = 1.16% (Interest Expense 8.54m / Debt 735.9m)
Taxrate = 26.49% (12.8m / 48.3m)
NOPAT = 37.3m (EBIT 50.7m * (1 - 26.49%))
Current Ratio = 1.19 (Total Current Assets 152.8m / Total Current Liabilities 128.6m)
Debt / Equity = 2.13 (Debt 735.9m / totalStockholderEquity, last quarter 346.0m)
Debt / EBITDA = 12.18 (Net Debt 731.0m / EBITDA 60.0m)
Debt / FCF = 15.44 (Net Debt 731.0m / FCF TTM 47.3m)
Total Stockholder Equity = 328.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.57% (Net Income 30.3m / Total Assets 956.5m)
RoE = 9.23% (Net Income TTM 30.3m / Total Stockholder Equity 328.5m)
RoCE = 10.29% (EBIT 50.7m / Capital Employed (Equity 328.5m + L.T.Debt 164.7m))
RoIC = 4.34% (NOPAT 37.3m / Invested Capital 859.8m)
WACC = 5.75% (E(1.41b)/V(2.14b) * Re(8.31%) + D(735.9m)/V(2.14b) * Rd(1.16%) * (1-Tc(0.26)))
Discount Rate = 8.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 7.74%
[DCF] Terminal Value 77.97% ; FCFF base≈31.9m ; Y1≈36.6m ; Y5≈53.8m
[DCF] Fair Price = 2.26 (EV 809.7m - Net Debt 731.0m = Equity 78.7m / Shares 34.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.42 | EPS CAGR: 24.33% | SUE: 0.77 | # QB: 0
Revenue Correlation: 99.44 | Revenue CAGR: 29.67% | SUE: 0.84 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.33 | Chg30d=+3.13% | Revisions=+38% | Analysts=7
EPS next Quarter (2026-09-30): EPS=0.34 | Chg30d=+0.85% | Revisions=+12% | Analysts=7
EPS current Year (2026-12-31): EPS=1.35 | Chg30d=+0.00% | Revisions=+67% | GrowthEPS=+14.6% | GrowthRev=+22.9%
EPS next Year (2027-12-31): EPS=1.59 | Chg30d=+0.00% | Revisions=+57% | GrowthEPS=+17.6% | GrowthRev=+7.8%
[Analyst] Revisions Ratio: +61% (up=17, down=3)